![Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial - The Lancet Oncology Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f3e9f102-d7b6-41ad-a6cd-2f371fb8b0f1/gr1.gif)
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial - The Lancet Oncology
![Nutrients | Free Full-Text | Evaluation of the Safety of a Plant-Based Infant Formula Containing Almonds and Buckwheat in a Neonatal Piglet Model Nutrients | Free Full-Text | Evaluation of the Safety of a Plant-Based Infant Formula Containing Almonds and Buckwheat in a Neonatal Piglet Model](https://www.mdpi.com/nutrients/nutrients-14-01499/article_deploy/html/images/nutrients-14-01499-g001-550.jpg)
Nutrients | Free Full-Text | Evaluation of the Safety of a Plant-Based Infant Formula Containing Almonds and Buckwheat in a Neonatal Piglet Model
![Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML | Leukemia Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-021-01125-4/MediaObjects/41375_2021_1125_Fig1_HTML.png)